Janice Richardson
Home Health · Fontana, CANPI 1073127841
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 386 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,404, 7.9 times the $433 reported in 2022.
Across 386 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$1K
- Vanda Pharmaceuticals Inc.$894
- AbbVie$807
- Otsuka America Pharmaceutical, Inc.$774
- plus $3K from 11 others
What the payments were for
- Food & beverage$9,17299%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 56 | $1,767 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $1,223 |
| Neurocrine Biosciences, Inc. | 31 | $1,059 |
| Vanda Pharmaceuticals Inc. | 45 | $894 |
| AbbVie | 40 | $807 |
| Otsuka America Pharmaceutical, Inc. | 39 | $774 |
| Alkermes, Inc. | 26 | $678 |
| Lundbeck LLC | 34 | $586 |
| Supernus Pharmaceuticals, Inc. | 19 | $391 |
| Axsome Therapeutics, Inc. | 14 | $346 |
| E.r. Squibb & Sons, L.L.C. | 13 | $326 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $100 |
| Sunovion Pharmaceuticals Inc. | 6 | $94 |
| Almatica Pharma LLC | 4 | $83 |
| Tris Pharma Inc | 3 | $54 |
| Noven Therapeutics, LLC | 2 | $36 |
| Johnson & Johnson | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few home health providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LybalviOlanzapine/Samidorphan Malate | 15 | $20,175 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,979 |
| Sertraline Hcl | 104 | $2,361 |
| Ramelteon | 15 | $997 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 24 | $939 |
| Buspirone Hcl | 97 | $907 |
| Quetiapine Fumarate | 28 | $436 |
| Bupropion XlBupropion Hcl | 17 | $395 |
| Fluoxetine Hcl | 57 | $236 |
| Prazosin Hcl | 19 | $234 |
| Aripiprazole | 35 | $220 |
| Duloxetine Hcl | 18 | $194 |
| Trazodone Hcl | 24 | $187 |
| Hydroxyzine Hcl | 31 | $168 |
| Lamotrigine | 17 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi | $678 | $20,17515 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $100 | $5,97911 claims |
| Almatica Pharma LLCSertraline Hcl | $83 | $2,361104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few home health providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other home health in Fontana
- Estrella GabrilloUpland$5K
- Margaret AshbyLong Beach$2K
- Catherine HillSacramento$684
- Jennifer Ty de GuzmanParamount$202
- Kim PierceShingle Springs$150
- Hayley OhlwilerSan Juan Capistrano$144
- Louis MarottaTemecula$127
- Gina MendozaMontclair$126
- Jennifer PerezModesto$23
- Nancy Gutierrez-FernandezSacramento$17
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.